{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Arrhythmia+Prophylaxis&page=2", "query": { "condition": "Arrhythmia Prophylaxis", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Arrhythmia+Prophylaxis&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T22:07:04.603Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00580216", "title": "Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Idrabiotaparinux sodium", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Placebo (for idrabiotaparinux)", "type": "DRUG" }, { "name": "Placebo (for warfarin)", "type": "DRUG" }, { "name": "Avidin", "type": "DRUG" }, { "name": "Placebo (for avidin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3773, "start_date": "2007-12", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2016-03-21", "last_synced_at": "2026-09-22T22:07:04.603Z", "location_count": 162, "location_summary": "Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Mountain Home", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580216" }, { "nct_id": "NCT00174785", "title": "A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Atrial Flutter" ], "interventions": [ { "name": "dronedarone (SR33589)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 4628, "start_date": "2005-06", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2010-01-12", "last_synced_at": "2026-09-22T22:07:04.603Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00174785" }, { "nct_id": "NCT00970489", "title": "Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Omega -3 fatty acids", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1516, "start_date": "2010-08", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2017-04-10", "last_synced_at": "2026-09-22T22:07:04.603Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00970489" }, { "nct_id": "NCT02283294", "title": "Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Transient Ischemic Attack", "Stroke", "Atrial Fibrillation" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2015-04", "completion_date": "2019-06", "has_results": true, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-09-22T22:07:04.603Z", "location_count": 5, "location_summary": "Torrance, California • St. Petersburg, Florida • Tampa, Florida + 1 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02283294" }, { "nct_id": "NCT00035464", "title": "Efficacy and Safety of Azimilide in the Prophylactic Treatment of Patients With Atrial Fibrillation.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Azimilide Dihydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 431, "start_date": "2000-12", "completion_date": "2004-01", "has_results": false, "last_update_posted_date": "2011-10-03", "last_synced_at": "2026-09-22T22:07:04.603Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 79 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00035464" }, { "nct_id": "NCT03440762", "title": "Atrial Fibrillation Screening and Education Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "AF awareness education", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2017-08-16", "completion_date": "2019-08-27", "has_results": false, "last_update_posted_date": "2020-09-14", "last_synced_at": "2026-09-22T22:07:04.603Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03440762" }, { "nct_id": "NCT02433379", "title": "Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ventricular Fibrillation", "Ventricular Tachycardia", "Low Cardiac Output" ], "interventions": [ { "name": "EMBLEM S-ICD System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 1173, "start_date": "2015-06-09", "completion_date": "2019-12-06", "has_results": true, "last_update_posted_date": "2025-03-24", "last_synced_at": "2026-09-22T22:07:04.603Z", "location_count": 69, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02433379" }, { "nct_id": "NCT00244725", "title": "Odiparcil For The Prevention Of Venous Thromboembolism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Deep Vein Thrombosis", "Fibrillation, Atrial", "Venous Thromboembolism", "Pulmonary Embolism" ], "interventions": [ { "name": "Odiparcil", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Coumadin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 961, "start_date": "2005-09", "completion_date": "2006-09", "has_results": true, "last_update_posted_date": "2017-05-02", "last_synced_at": "2026-09-22T22:07:04.603Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Banning", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00244725" }, { "nct_id": "NCT00402363", "title": "Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fibrillation, Atrial" ], "interventions": [ { "name": "omega-3-acid ethyl esters", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 663, "start_date": "2006-11", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-09-22T22:07:04.603Z", "location_count": 178, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 149 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Cottonwood", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402363" }, { "nct_id": "NCT07626411", "title": "Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation (AF)" ], "interventions": [ { "name": "REGN7508", "type": "DRUG" }, { "name": "Apixaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15364, "start_date": "2026-08-10", "completion_date": "2029-12-10", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-22T22:07:04.603Z", "location_count": 32, "location_summary": "Alexander City, Alabama • Dothan, Alabama • Glendale, Arizona + 28 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Fremont", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07626411" } ] }